155 related articles for article (PubMed ID: 1909407)
1. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.
Matsuno H; Uematsu T; Nagashima S; Nakashima M
J Pharmacol Methods; 1991 Jul; 25(4):303-17. PubMed ID: 1909407
[TBL] [Abstract][Full Text] [Related]
2. Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Matsuno H; Uematsu T; Umemura K; Takiguchi Y; Wada K; Nakashima M
Br J Pharmacol; 1992 Jul; 106(3):533-8. PubMed ID: 1387025
[TBL] [Abstract][Full Text] [Related]
3. Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
Takiguchi Y; Hirata Y; Wada K; Nakashima M
Thromb Res; 1992 Aug; 67(4):435-45. PubMed ID: 1412222
[TBL] [Abstract][Full Text] [Related]
4. A canine coronary artery thrombosis model: application of photochemically induced thrombosis.
Umemura K; Ishiye M; Araki S; Nakashima M
Arch Int Pharmacodyn Ther; 1995; 330(1):13-24. PubMed ID: 8849307
[TBL] [Abstract][Full Text] [Related]
5. Vessel wall injury and arterial thrombosis induced by a photochemical reaction.
Saniabadi AR; Umemura K; Matsumoto N; Sakuma S; Nakashima M
Thromb Haemost; 1995 May; 73(5):868-72. PubMed ID: 7482418
[TBL] [Abstract][Full Text] [Related]
6. Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Shebuski RJ; Storer BL; Fujita T
Thromb Res; 1988 Dec; 52(5):381-92. PubMed ID: 3146820
[TBL] [Abstract][Full Text] [Related]
7. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
8. Use of tissue plasminogen activator for femoral artery thrombosis following transcatheter coil occlusion of patent ductus arteriosus.
Carlson KM; Rutledge JM; Parker BR; Grifka RG
Pediatr Cardiol; 2005; 26(1):83-6. PubMed ID: 15793657
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Higo K; Karasawa A; Kubo K
Arzneimittelforschung; 1991 Dec; 41(12):1251-5. PubMed ID: 1815525
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
Kawasaki T; Kaku S; Sakai Y; Takenaka T
J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506
[TBL] [Abstract][Full Text] [Related]
11. A novel platelet-rich arterial thrombosis model in rabbits. Simple, reproducible, and dynamic real-time measurement by using double-opposing inverted-sutures model.
Shieh SJ; Chiu HY; Shi GY; Wu CM; Wang JC; Chen CH; Wu HL
Thromb Res; 2001 Sep; 103(5):363-76. PubMed ID: 11553369
[TBL] [Abstract][Full Text] [Related]
12. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Ramjit DR; Lynch JJ; Sitko GR; Mellott MJ; Holahan MA; Stabilito II; Stranieri MT; Zhang G; Lynch RJ; Manno PD
J Pharmacol Exp Ther; 1993 Sep; 266(3):1501-11. PubMed ID: 8371153
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Mellott MJ; Holahan MA; Lynch JJ; Vlasuk GP; Dunwiddie CT
Circ Res; 1992 Jun; 70(6):1152-60. PubMed ID: 1576736
[TBL] [Abstract][Full Text] [Related]
14. Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Fujita T; Hasan S; Storer BL; Shebuski RJ
Fundam Clin Pharmacol; 1989; 3(6):643-53. PubMed ID: 2533138
[TBL] [Abstract][Full Text] [Related]
15. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model.
Umemura K; Toshima Y; Asai F; Nakashima M
Thromb Res; 1995 Jun; 78(5):379-87. PubMed ID: 7660354
[TBL] [Abstract][Full Text] [Related]
16. Occlusive thrombosis in the femoral artery of the rabbit: a pharmacological model for evaluating antiplatelet and anticoagulant agents.
Sugidachi A; Asai F; Tani Y; Hosokawa T; Koike H
Blood Coagul Fibrinolysis; 1996 Jan; 7(1):57-64. PubMed ID: 8845464
[TBL] [Abstract][Full Text] [Related]
17. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis.
Jang IK; Gold HK; Ziskind AA; Fallon JT; Holt RE; Leinbach RC; May JW; Collen D
Circulation; 1989 Apr; 79(4):920-8. PubMed ID: 2494006
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Nishiyama H; Umemura K; Saniabadi AR; Takiguchi Y; Uematsu T; Nakashima M
Eur J Pharmacol; 1994 Oct; 264(2):191-8. PubMed ID: 7851482
[TBL] [Abstract][Full Text] [Related]
19. Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model.
Umemura K; Toshima Y; Nakashima M
Eur J Pharmacol; 1994 Sep; 262(1-2):27-31. PubMed ID: 7813575
[TBL] [Abstract][Full Text] [Related]
20. Heparin cofactor II inhibits thrombus formation in a rat thrombosis model.
Yamanaga K; Yuuki T; Tsukada M; Koshiba H; Nakajima T; Takechi K; Nakamura N
Thromb Res; 2000 Apr; 98(1):95-101. PubMed ID: 10706937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
